Maura Furey
Neurocrine Biosciences (United States)(US)
Publications by Year
Research Areas
Treatment of Major Depression, Mental Health Research Topics, Functional Brain Connectivity Studies, Tryptophan and brain disorders, Schizophrenia research and treatment
Most-Cited Works
- → Synaptic Potentiation Is Critical for Rapid Antidepressant Response to Ketamine in Treatment-Resistant Major Depression(2012)198 cited
- → BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders(2015)135 cited
- → Abnormal brain glucose metabolism in the delusional misidentification syndromes: A positron emission tomography study in Alzheimer disease(1995)120 cited
- → Network analysis of PET-mapped visual pathways in Alzheimer type dementia(1995)114 cited
- → Investigating the neuroimmunogenic architecture of schizophrenia(2017)70 cited
- → Analysis of the caudate nucleus transcriptome in individuals with schizophrenia highlights effects of antipsychotics and new risk genes(2022)65 cited
- → Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants(2018)62 cited
- → Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression(2018)38 cited
- → Dissociable temporal effects of bupropion on behavioural measures of emotional and reward processing in depression(2018)37 cited
- → Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder(2018)36 cited